Opinion|Videos|February 5, 2025
Additional Considerations With PBC Therapies
Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How have recent FDA actions regarding obeticholic acid influenced perceptions of its long-term use in PBC treatment, and what broader implications might these regulatory actions have for patients and providers?
- How can health care teams support patients in navigating potential access or coverage challenges that may arise due to regulatory changes affecting PBC therapies, especially when considering a switch to newer treatments?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expanded Approval of Imiglucerase Expands Treatment Options for Type 3 Gaucher Disease
2
Study Finds No Evidence That Hormone Therapy Use Affects Dementia Risk in Postmenopausal Women
3
FDA Draft Guidance Signals Shift Toward MRD, Complete Response as Accelerated Approval End Points in Multiple Myeloma
4
FDA Approves Daratumumab and Hyaluronidase-fihj With Quadruplet Regimen for Newly Diagnosed Multiple Myeloma
5